Soligenix (SNGX) vs Traws Pharma (TRAW)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Soligenix is the larger company by market cap ($7.5 million vs $7.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SNGX | TRAW |
|---|---|---|
| Share price | $0.3466 | $0.4803 |
| Market cap | $7.54M | $7.38M |
| 1-day change | -1.95% | +0.27% |
| EPS (TTM) | $-0.79 | $-1.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.97 | $3.27 |
| 52-week low | $0.28 | $0.43 |
| Distance from 52-week high | -82.41% | -85.31% |
| Analyst consensus | none | none |
| Avg. price target upside | +298.15% | +108.20% |
| Average volume | 253.75K | 569.02K |
| Shares outstanding | 21.77M | 15.37M |
| Employees | 13 | 4 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Soligenix
SNGX stock →Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions.
Healthcare · Biotechnology · 13 employees
About Traws Pharma
TRAW stock →Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza.
Healthcare · Biotechnology · 4 employees
SNGX vs TRAW FAQ
Which is bigger, Soligenix or Traws Pharma?
Soligenix (SNGX) is larger, with a market capitalization of $7.54M compared with $7.38M for Traws Pharma (TRAW).
Are Soligenix and Traws Pharma in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.